W.ArchibaldY
In GSCs, the PRRX2/GCH1/BH4 axis provides additional protection against ferroptosis
Retatrutide (LY3437943) is an investigational triple receptor agonist (GLP-1, GIP, and glucagon) studied for obesity and metabolic outcomes
Dixon SJ, Patel DN, Welsch M, Skouta R, Lee ED, Hayano M, Thomas AG, Gleason CE, Tatonetti NP, Slusher BS, Stockwell BR
Some patients feel as though they want more frequent injections, and occasionally we test levels to see if they are receiving adequate replacement, but Im not sure how strong the evidence is to support this. Want news like this straight to your inbox
Nishida Y, Heinz- Montoya R, Morita K, Tanaka T, Wang F, Takahashi K, Ishizawa J, Kumar P, Patel P, Dos Santos CE, DiNardo CD, Andreeff M